Anti-PD-1 immunotherapy drug

Nivolumab ( Opdivo ), an anti-PD-1 immune checkpoint inhibitor, significantly prolongs survival in patients with advanced kidney cancer, whose disease...


Results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared...